表紙
市場調查報告書
商品編碼
1019786

偏頭痛:流行病學的預測 (到2030年)

Migraine - Epidemiology Forecast to 2030

出版日期: | 出版商: GlobalData | 英文 38 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球主要7個國家(7MM),過去12個月的偏頭痛的患病者總數,預計從2020年的7273萬9456人,增加到2030年的7370萬8346人。還有在預測期間內的AGR預計成為0.13%。女性比男性的患病者多,以及青年人有大量發病的趨勢。

本報告提供全球主要7個國家(美國,法國,德國,義大利,西班牙,英國,日本) 的偏頭痛的發病情形與今後預測相關分析,疾病的特徵和目前患病者的發病情形 (近期的12個月份),今後10年的患病人數趨勢預測,男女、各年齡、各類型、各頻率等詳細趨勢等調查。

目錄

第1章 目錄

第2章 偏頭痛:摘要整理

第3章 流行病學

  • 疾病的背景情況
  • 危險因素與並存症
  • 全球過去趨勢
  • 主要國家 (7MM)的已受診發病者數的趨勢
    • 資訊來源
    • 預測的前提條件與方法
    • 預測的前提條件與方法:偏頭痛的患病人數 (近期12個月)
    • 預測的前提條件與方法:偏頭痛的患病人數 (近期12個月),各頻率
    • 偏頭痛的患病人數 (近期12個月),各類型
    • 偏頭痛的已受診患病人數 (近期12個月)
  • 偏頭痛的流行病學的預測 (2020年∼2030年)
    • 偏頭痛的整體患病人數 (近期12個月)
    • 偏頭痛的整體患病人數 (近期12個月):各年齡
    • 偏頭痛的整體患病人數 (近期12個月):男女
    • 偏頭痛的整體患病人數 (近期12個月):各頻率 (一次性/慢性)
    • 偏頭痛的整體患病人數 (近期12個月):各類型
    • 偏頭痛的已受診患病人數 (近期12個月)
  • 討論
    • 流行病學的預測的考察
    • 新型冠狀病毒感染疾病 (COVID-19)的影響
    • 分析的限制
    • 分析的優勢

第3章 附錄

目錄
Product Code: GDHCER275-21

Migraine is a common neurological disorder characterized by intense, debilitating headaches. It is characterized by a unilateral, pulsating, or throbbing pain that is moderate to severe and is aggravated by physical activity. According to the International Classification of Headache Disorders, Third Edition (ICHD-3) criteria, migraine is considered to be one of two types based on the presence of characteristic transient focal neurological symptoms that usually precede or sometimes accompany the headache: migraine with aura, and migraine without aura (Olesen, 2018). According to the frequency of headaches, migraine can be divided into episodic migraine with the primary criterion of less than 15 headache days per month and chronic migraine with 15 or more headache days per month (Buse et al., 2012; Olesen, 2018).

This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes a 10-year epidemiology forecast for the 12-month total prevalent cases and 12-month diagnosed prevalent cases of migraine. The 12-month total prevalent cases and 12-month diagnosed prevalent cases of migraine are segmented by age (18 years and older), sex, subtype (migraine with aura and migraine without aura). The report also includes the 12-month total and 12-month diagnosed prevalent cases of migraine further segmented by migraine frequency into episodic migraine and chronic migraine for both sexes and ages 18 years and older. The following data describes epidemiology of migraine. In the 7MM, GlobalData epidemiologists forecast an increase in the 12-month total prevalent cases of migraine from 72,739,456 cases in 2020 to 73,708,346 cases in 2030, at an AGR of 0.13% over the forecast period. Women accounted for more 12-month total prevalent cases of migraine than men in the 7MM and it predominantly affects younger adults. These findings are in line with the GlobalData estimates and these trends are reflected in GlobalData's forecast for the 12-month total prevalent cases for the 7MM.

Scope

  • The Migraine Epidemiology Report provides an overview of the risk factors and global trends of Migraine in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the 12-month total prevalent cases and 12-month diagnosed prevalent cases of migraine segmented by sex and age (ages ≥18 years). The 12-month total prevalent cases and 12-month diagnosed prevalent cases of migraine are further segmented by subtype (migraine with aura and migraine without aura). The report also includes the 12-month total and 12-month diagnosed prevalent cases of migraine further segmented by migraine frequency into episodic migraine and chronic migraine for both sexes and ages 18 years and older.
  • The migraine epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Migraine Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global migraine market.
  • Quantify patient populations in the global migraine market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for migraine therapeutics in each of the markets covered.
  • Understand magnitude of migraine population by subtype, and migraine frequency.

Table of Contents

Table of Contents

1 Migraine: Executive Summary

  • 1.1 Catalyst
  • 1.2 Related Reports
  • 1.3 Upcoming Reports

2 Epidemiology

  • 2.1 Disease Background
  • 2.2 Risk Factors and Comorbidities
  • 2.3 Global and Historical Trends
  • 2.4 7MM Forecast Methodology
    • 2.4.1 Sources
    • 2.4.2 Forecast Assumptions and Methods
    • 2.4.3 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine
    • 2.4.4 Forecast Assumptions and Methods: 12-Month Total Prevalent Cases of Migraine by Frequency
    • 2.4.5 12-Month Total Prevalent Cases of Migraine by Type
    • 2.4.6 12-Month Diagnosed Prevalent Cases of Migraine
  • 2.5 Epidemiological Forecast for Migraine (2020-2030)
    • 2.5.1 12-Month Total Prevalent Cases of Migraine
    • 2.5.2 Age-Specific 12-Month Total Prevalent Cases of Migraine
    • 2.5.3 Sex-Specific 12-Month Total Prevalent Cases of Migraine
    • 2.5.4 12-Month Total Prevalent Cases of Migraine by Frequency of Episodic and Chronic
    • 2.5.5 12-Month Total Prevalent Cases of Migraine by Type
    • 2.5.6 12-Month Diagnosed Prevalent Cases of Migraine
  • 2.6 Discussion
    • 2.6.1 Epidemiological Forecast Insight
    • 2.6.2 COVID-19 Impact
    • 2.6.3 Limitations of the Analysis
    • 2.6.4 Strengths of the Analysis

3 Appendix

  • 3.1 Bibliography
  • 3.2 About the Authors
    • 3.2.1 Epidemiologist
    • 3.2.2 Reviewers
    • 3.2.3 Global Director of Therapy Analysis and Epidemiology
    • 3.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • Contact Us

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for Migraine

List of Figures

List of Figures

  • Figure 1: 7MM, 12-Month Total Prevalent Cases of Migraine, Both Sexes, N, Ages ≥18 Years, 2020 and 2030
  • Figure 2: 7MM, 12-Month Diagnosed Prevalent Cases of Migraine, Both Sexes, N, Ages ≥18 Years, 2020 and 2030
  • Figure 3: 7MM, 12-Month Total Prevalence of Migraine, Men and Women, %, Ages ≥18 Years, 2020
  • Figure 4: 7MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of Migraine
  • Figure 5: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Frequency
  • Figure 6: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of Migraine by Type
  • Figure 7: 7MM, Sources Used to Forecast the Diagnosis Rate of Migraine
  • Figure 8: 7MM, 12-Month Total Prevalent Cases of Migraine, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 9: 7MM, 12-Month Total Prevalent Cases of Migraine by Age, N, Both Sexes, 2020
  • Figure 10: 7MM, 12-Month Total Prevalent Cases of Migraine by Sex, N, Ages ≥18 Years, 2020
  • Figure 11: 7MM, 12-Month Total Prevalent Cases of Migraine by Frequency, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 12: 7MM, 12-Month Total Prevalent Cases of Migraine by Type, N, Both Sexes, Ages ≥18 Years, 2020
  • Figure 13: 7MM, 12-Month Diagnosed Prevalent Cases of Migraine, N, Both Sexes, Ages ≥18 Years, 2020